TDAC
Translational Development Acquisition Corp.10.42
+0.00+0%
Dec 15, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
228.28MP/E (TTM)
47.36Basic EPS (TTM)
0.22Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Translational Development Acquisition Corp. swung to a net income of $1.6M for Q2 FY2025 ended June 30, 2025, up from a $1.7K loss a year earlier, thanks to $1.8M in dividends from its Trust Account offsetting $221K in administrative costs—yet operating losses widened to $221K from $1.7K as public company expenses mounted. For the half-year, net income hit $3.1M on $3.7M dividends against $569K costs, with diluted EPS at $0.14 on 17.25M redeemable shares, fully reconciling without anti-dilution quirks. Cash dipped to $35K amid $403K used in operations, but the Trust swelled to $178M, backed by no debt beyond a $6M deferred underwriting fee and fresh Sponsor note up to $2M post-quarter. No M&A yet, just the hunt. Geopolitical tensions could snag the deal search.
8-K
Sponsor loans up to $2M
Translational Development Acquisition Corp. secured a non-interest-bearing promissory note from sponsor TDAC Partners LLC on August 8, 2025, allowing draws up to $2,000,000 for working capital. Repayable at the earlier of the business combination deadline or closing, the note forgives unpaid amounts if no deal materializes, barring trust account funds. This bridges cash needs. Yet risks linger if no merger occurs.
10-Q
Q1 FY2025 results
Translational Development Acquisition Corp. posted a net income of $1.5M for Q1 ended March 31, 2025, driven by $1.8M in dividends from its Trust Account, offsetting $0.3M in general and administrative costs—its first results since the December 2024 IPO. The Trust grew to $176.2M, up from $174.4M at year-end, while cash dipped to $0.2M from $0.4M, with operating cash use at $0.2M. No revenue yet, as it's a blank-check firm hunting a business combination by June 2026. Liquidity holds via potential Working Capital Loans up to $1.5M. Solid Trust yields keep things afloat. Yet geopolitical tensions could disrupt the deal hunt.
10-K
FY2024 results
Translational Development Acquisition Corp., a blank check company, completed its IPO on December 24, 2024, raising $172.5M in gross proceeds from 17.25M units at $10 each, with $174.2M placed in trust yielding $10.10 per share. For FY2024 ended December 31, 2024, the firm reported a net loss of $71K, driven by $196K in operating costs offset by $125K unrealized gains on trust securities— a sharp improvement from 2023's $486K loss amid pre-IPO setup. Q4 momentum surged with the IPO closing, injecting liquidity for target pursuits, while cash outside trust stood at $438K to fund due diligence. No dividends or buybacks occurred; the sponsor provides $10K monthly admin support. No annual guidance disclosed, but the 18-month merger window looms. Yet sponsor conflicts could snag deal flow.
IPO
Sector
Industry
DTSQ
DT Cloud Star Acquisition Corpo
10.75-0.06
KVAC
Keen Vision Acquisition Corpora
11.79+0.00
RDAC
Rising Dragon Acquisition Corp.
9.60+0.15
RTAC
Renatus Tactical Acquisition Co
10.59+0.07
SDHI
Siddhi Acquisition Corp
10.25+0.00
TACH
Titan Acquisition Corp.
10.24-0.01
TACO
Berto Acquisition Corp.
10.13+0.00
TAVI
Tavia Acquisition Corp.
10.41+0.00
VACH
Voyager Acquisition Corp
10.57+0.00
YOTA
Yotta Acquisition Corporation
2.00+0.00